Angiogenex Inc AGGX:Over The Counter Mkt

RT Quote | Exchange | USD
Last | 08/27/21 GMT
0.1313UNCH (UNCH)
52 week range
0.11 - 0.40
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.1313
  • 52 Week High0.40
  • 52 Week High Date08/02/21
  • 52 Week Low0.11
  • 52 Week Low Date06/28/21

Key Stats

  • Market Cap3.99M
  • Shares Out30.39M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta7.46
  • YTD % Change-

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.1313
  • 52 Week High0.40
  • 52 Week High Date08/02/21
  • 52 Week Low0.11
  • 52 Week Low Date06/28/21
  • Market Cap3.99M
  • Shares Out30.39M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta7.46
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-0.03
  • P/E (TTM)-4.42
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-895,000.00
  • ROE (TTM)-
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-13.46%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Angiogenex Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
AngioGenex, Inc. is a biopharmaceutical company that is engaged in the discovery and development of Id protein inhibitors to address unmet medical needs in oncology and ophthalmology. The Company’s lead candidate AGX-A is a novel small molecule being investigated for the treatment of cholangiocarcinoma (a form of liver cancer) and age-related macular degeneration. The Company’s Anti-Id platform gave rise to AGX-A, which is an investigational small molecule designed to...
Michael Aronstein
Chairman of the Board, President, Chief Executive Officer
Michael Strage J.D.
Vice President, Chief Operations Officer, Business Development, Director
Martin Murray CPA
Chief Financial Officer, Director
Address
425 Madison Ave Ste 902
New York, NY
10017-1110
United States